Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results

被引：0
|
作者：
Seneviratne, Lasika C.
Harnden, Kathleen Kiernan
Blau, Sibel
Danso, Michael A.
Berz, David
Guaqueta, Delia Constanza
Schwerkoske, John F.
O'Shaughnessy, Joyce
Patt, Debra A.
Bardia, Aditya
McCann, Kelly Elizabeth
Beelen, Andrew Paul
Zhang, Jingshan
Yi, John S.
Hurvitz, Sara A.
Mardones, Mabel Alejandra
机构：
[1] Los Angeles Canc Network, Los Angeles, CA USA
[2] Inova Schar Canc Inst, Fairfax, VA USA
[3] Northwest Med Specialties, Puyallup, WA USA
[4] Virginia Oncol Associates, Norfolk, VA USA
[5] Virginia Oncol Associates, Virginia Beach, VA USA
[6] Valkyrie Clin Trials Inc, Los Angeles, CA USA
[7] Mem Reg Hosp, Hollywood, FL USA
[8] Minnesota Oncol Hematol PA, Woodbury, MN USA
[9] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[10] Texas Oncol, US Oncol Network, Austin, TX USA
[11] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[12] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA
[13] Beverly Hills Canc Care, Los Angeles, CA USA
[14] G1 Therapeut Inc, Res Triangle Pk, NC USA
[15] Univ Washington Sch Med, Seattle, WA USA
[16] Fred Hutchinson Canc Ctr, Seattle, WA USA
[17] Rocky Mt Canc Ctr, Sarah Cannon Res Inst, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1091
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
    Hanna, Daire
    Merrick, Sophie
    Ghose, Aruni
    Devlin, Michael John
    Yang, Dorothy D.
    Phillips, Edward
    Okines, Alicia
    Chopra, Neha
    Papadimatraki, Elisavet
    Ross, Kirsty
    Macpherson, Iain
    Boh, Zhuang Y.
    Michie, Caroline O.
    Swampillai, Angela
    Gupta, Sunnia
    Robinson, Tim
    Germain, Lewis
    Twelves, Chris
    Atkinson, Charlotte
    Konstantis, Apostolos
    Riddle, Pippa
    Cresti, Nicola
    Naik, Jay D.
    Borley, Annabel
    Guppy, Amy
    Schmid, Peter
    Phillips, Melissa
    BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1916 - 1920
  • [42] Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
    Chen, Jigang
    Han, Mingyang
    Liu, Aihua
    Shi, Bo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC)
    Bardia, Aditya
    Rugo, Hope S.
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2018, 78 (04)
  • [44] A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    Brufsky, Adam
    Cortes, Javier
    Loibl, Sibylle
    Piccart, M.
    Cowden, Janice
    Spears, Patty
    Carey, Lisa A.
    FUTURE ONCOLOGY, 2021, 17 (30) : 3911 - 3924
  • [45] Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.
    Bardia, Aditya
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Oliveira, Mafalda
    Rugo, Hope S.
    Brufsky, Adam
    Kalinsky, Kevin
    Cortes, Javier
    O'Shaughnessy, Joyce
    Dieras, Veronique C.
    Carey, Lisa A.
    Gianni, Luca
    Piccart-Gebhart, Martine J.
    Loibl, Sibylle
    Zhu, Yanni
    Phan, See-Chun
    Hurvitz, Sara A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    O'Shaughnessy, Joyce
    Brufsky, Adam
    Rugo, Hope S.
    Tolaney, Sara M.
    Punie, Kevin
    Sardesai, Sagar
    Hamilton, Erika
    Loirat, Delphine
    Traina, Tiffany
    Leon-Ferre, Roberto
    Hurvitz, Sara A.
    Kalinsky, Kevin
    Bardia, Aditya
    Henry, Stephanie
    Mayer, Ingrid
    Zhu, Yanni
    Phan, See
    Cortes, Javier
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (02) : 127 - 139
  • [47] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    Joyce O’Shaughnessy
    Adam Brufsky
    Hope S. Rugo
    Sara M. Tolaney
    Kevin Punie
    Sagar Sardesai
    Erika Hamilton
    Delphine Loirat
    Tiffany Traina
    Roberto Leon-Ferre
    Sara A. Hurvitz
    Kevin Kalinsky
    Aditya Bardia
    Stephanie Henry
    Ingrid Mayer
    Yanni Zhu
    See Phan
    Javier Cortés
    Breast Cancer Research and Treatment, 2022, 195 : 127 - 139
  • [48] Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
    Weiss, Jennifer
    Glode, Ashley
    Messersmith, Wells A.
    Diamond, Jennifer
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 673 - 679
  • [49] Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)
    O'Shaughnessy, J.
    Brufsky, A.
    Rugo, H. S.
    Tolaney, S. M.
    Diab, S.
    Punie, K.
    Sardesai, S.
    Hamilton, E.
    Loirat, D.
    Traina, T. A.
    Leon-Ferre, R.
    Hurvitz, S. A.
    Kalinsky, K.
    Bardia, A.
    Henry, S.
    Mayer, I.
    Hong, Q.
    Phan, S.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S473 - S474
  • [50] Efficacy of sacituzumab govitecan based regimen in triple-negative breast cancer: A systematic review.
    Khalid, Farhan
    Kashyap, Richi
    Singh, Vinit
    Tayyeb, Muhammad
    Jaan, Ali
    Mohan, Gaurav
    Meghal, Trishala
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345